Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

European Journal of Medicinal Chemistry

Volumn 113, Issue , 2016, Pages 246-257

  Li, Zheng ^a   Qiu, Qianqian ^a   Xu, Xue ^a   Wang, Xuekun ^a   Jiao, Lei ^a   Su, Xin ^a   Pan, Miaobo ^a   Huang, Wenlong ^a   Qian, Hai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Dihedral angle; FFA1 agonist; GPR40; Heteroaromatics; Liver toxicity; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; GLIBENCLAMIDE; GLUCOSE; THIAZOLE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM TRANSPORT; CHO CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG MEGADOSE; DRUG SYNTHESIS; FEMALE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; LIVER TOXICITY; MALE; MOLECULAR MODEL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL CHEMISTRY; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HUMAN; SYNTHESIS;

ANIMALS; BLOOD GLUCOSE; CHO CELLS; CRICETULUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84959362883     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.02.040     Document Type: Article

References (54)

1. R.A. DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
2. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, J.K. Lin, F. Farzadfar, Y.-H. Khang, G.A. Stevens, M. Rao, M.K. Ali, L.M. Riley, C.A. Robinson, M. Ezzati, and C Global Burden Metab Risk Factors National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
3. O.J. Phung, J.M. Scholle, M. Talwar, and C.I. Coleman Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 2010 1410 1418
4. M.A. Avery, C.S. Mizuno, A.G. Chittiboyina, T.W. Kurtz, and H.A. Pershadsingh Type 2 diabetes and oral antihyperglycemic drugs Curr. Med. Chem. 15 2008 61 74
5. S.A. Stein, E.M. Lamos, and S.N. Davis A review of the efficacy and safety of oral antidiabetic drugs Expert Opin. Drug Saf. 12 2013 153 175
6. H.E. Lebovitz Type 2 diabetes mellitus-current therapies and the emergence of surgical options Nat. Rev. Endocrinol. 7 2011 408 419
7. A.A. Tahrani, C.J. Bailey, S. Del Prato, and A.H. Barnett Management of type 2 diabetes: new and future developments in treatment Lancet 378 2011 182 197
8. X. Xu, G. Wang, T. Zhou, L. Chen, J. Chen, and X. Shen Novel approaches to drug discovery for the treatment of type 2 diabetes Expert Opin. Drug Dis. 9 2014 1047 1058
9. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinobara, S. Hinuma, Y. Fujisawa, and M. Fujino Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 Nature 422 2003 173 176
10. C.P. Briscoe, M. Tadayyon, J.L. Andrews, W.G. Benson, J.K. Chambers, M.M. Eilert, C. Ellis, N.A. Elshourbagy, A.S. Goetz, D.T. Minnick, P.R. Murdock, H.R. Sauls, U. Shabon, L.D. Spinage, J.C. Strum, P.G. Szekeres, K.B. Tan, J.M. Way, D.M. Ignar, S. Wilson, and A.I. Muir The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 278 2003 11303 11311
11. L.A. Stoddart, N.J. Smith, and G. Milligan International union of pharmacology. LXXI. Free fatty acid receptors FFA1,-2, and-3: pharmacology and pathophysiological functions Pharmacol. Rev. 60 2008 405 417
12. P. Wellendorph, L.D. Johansen, and H. Bräuner-Osborne Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients Mol. Pharmacol. 76 2009 453 465
13. H. Shapiro, S. Shachar, I. Sekler, M. Hershfinkel, and M.D. Walker Role of GPR40 in fatty acid action on the β cell line INS-1E Biochem. Biophys. Res. Commun. 335 2005 97 104
14. 2+ channel and link to insulin release Am. J. Physiol. Endocrinol. Metab. 289 2005 670 677
15. N. Negoro, S. Sasaki, S. Mikami, M. Ito, M. Suzuki, Y. Tsujihata, R. Ito, A. Harada, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, M. Funami, T. Tanaka, A. Kogame, S. Matsunaga, T. Yasuma, and Y. Momose Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 1 2010 290 294
16. S. Mikami, S. Kitamura, N. Negoro, S. Sasaki, M. Suzuki, Y. Tsujihata, T. Miyazaki, R. Ito, N. Suzuki, J. Miyazaki, T. Santou, N. Kanzaki, M. Funami, T. Tanaka, T. Yasuma, and Y. Momose Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes J. Med. Chem. 55 2012 3756 3776
17. N. Negoro, S. Sasaki, M. Ito, S. Kitamura, Y. Tsujihata, R. Ito, M. Suzuki, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, M. Funami, T. Tanaka, T. Yasuma, and Y. Momose Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists J. Med. Chem. 55 2012 1538 1552
18. N. Negoro, S. Sasaki, S. Mikami, M. Ito, Y. Tsujihata, R. Ito, M. Suzuki, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, M. Funami, A. Morohashi, M. Nonaka, S. Matsunaga, T. Yasuma, and Y. Momose Optimization of (2, 3-dihydro-1-benzofuran-3-yl) acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent J. Med. Chem. 55 2012 3960 3974
19. S.C. McKeown, D.F. Corbett, A.S. Goetz, T.R. Littleton, E. Bigham, C.P. Briscoe, A.J. Peat, S.P. Watson, and D.M. Hickey Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor Bioorg. Med. Chem. Lett. 17 2007 1584 1589
20. J.B. Houze, L. Zhu, Y. Sun, M. Akerman, W. Qiu, A.J. Zhang, R. Sharma, M. Schmitt, Y. Wang, J. Liu, J. Liu, J.C. Medina, J.D. Reagan, J. Luo, G. Tonn, J. Zhang, J.Y.-L. Lu, M. Chen, E. Lopez, K. Nguyen, L. Yang, L. Tang, H. Tian, S.J. Shuttleworth, and D.C.H. Lin AMG 837: a potent, orally bioavailable GPR40 agonist Bioorg. Med. Chem. Lett. 22 2012 1267 1270
21. S.P. Brown, P.J. Dransfield, M. Vimolratana, X. Jiao, L. Zhu, V. Pattaropong, Y. Sun, J. Liu, J. Luo, J. Zhang, S. Wong, R. Zhuang, Q. Guo, F. Li, J.C. Medina, G. Swaminath, D.C.H. Lin, and J.B. Houze Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist ACS Med. Chem. Lett. 3 2012 726 730
22. Y. Wang, J. Liu, P.J. Dransfield, L. Zhu, Z. Wang, X. Du, X. Jiao, Y. Su, A.-r. Li, S.P. Brown, A. Kasparian, M. Vimolratana, M. Yu, V. Pattaropong, J.B. Houze, G. Swaminath, T. Thanhvien, N. Khanh, Q. Guo, J. Zhang, R. Zhuang, F. Li, L. Miao, M.D. Bartberger, T.L. Correll, D. Chow, S. Wong, J. Luo, D.C.H. Lin, and J.C. Medina Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles ACS Med. Chem. Lett. 4 2013 551 555
23. E. Defossa, and M. Wagner Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 24 2014 2991 3000
24. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 64 2012 4 17
25. E. Christiansen, C. Urban, M. Grundmann, M.E. Due-Hansen, E. Hagesaether, J. Schmidt, L. Pardo, S. Ullrich, E. Kostenis, M. Kassack, and T. Ulven Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties J. Med. Chem. 54 2011 6691 6703
26. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Dis. 5 2010 235 248
27. G.M. Keserü, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discov. 8 2009 203 212
28. P.D. Leeson, and R.J. Young Molecular property design: does everyone get it? ACS Med. Chem. Lett. 6 2015 722 725
29. M.P. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 51 2008 817 834
30. N.A. Meanwell Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 54 2011 2529 2591
31. N.A. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24 2011 1420 1456
32. E. Christiansen, M.E. Due-Hansen, C. Urban, M. Grundmann, R. Schröder, B.D. Hudson, G. Milligan, M.A. Cawthorne, E. Kostenis, M.U. Kassack, and T. Ulven Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties J. Med. Chem. 55 2012 6624 6628
33. C.F. Burant, P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, B. Xie, and E. Leifke TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial Lancet 379 2012 1403 1411
34. K. Kaku, T. Araki, and R. Yoshinaka Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes Diabetes Care 36 2013 245 250
35. M.S. Hedrington, and S.N. Davis Discontinued in 2013: diabetic drugs Expert. Opin. Inv. Drug. 23 2014 1703 1711
36. X. Wang, T. Zhao, B. Yang, Z. Li, J. Cui, Y. Dai, Q. Qiu, H. Qiang, W. Huang, and H. Qian Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists Bioorg. Med. Chem. 23 2015 132 140
37. J. Balsells, L. DiMichele, J. Liu, M. Kubryk, K. Hansen, and J.D. Armstrong Synthesis of [1, 2, 4] triazolo [4, 3-α] piperazines via highly reactive chloromethyloxadiazoles Org. Lett. 7 2005 1039 1042
38. P. Kotian, S.W. Mascarella, P. Abraham, A.H. Lewin, J.W. Boja, M.J. Kuhar, and F.I. Carroll Synthesis, ligand binding, and quantitative structure-activity relationship study of 3β-(4′-substituted phenyl)-2β-heterocyclic tropanes: evidence for an electrostatic interaction at the 2β-position J. Med. Chem. 39 1996 2753 2763
39. N. Boechat, J.C.S. da Costa, J. de Souza Mendonça, P.S.M. de Oliveira, and M. VinÍcius Nora De Souza A simple reduction of methyl aromatic esters to alcohols using sodium borohydride-methanol system Tetrahedron Lett. 45 2004 6021 6022
40. A. Schmidt, T. Habeck, M.K. Kindermann, and M. Nieger New pyrazolium-carboxylates as structural analogues of the pseudo-cross-conjugated betainic alkaloid Nigellicine J. Org. Chem. 68 2003 5977 5982
41. C.R. Hauser, F.W. Swamer, and J.T. Adams The acylation of ketones to form β-diketones or β-keto aldehydes Org. React. 8 1954 59 196
42. E.E. Royals The use of sodium methoxide in the Claisen reaction J. Am. Chem. Soc. 67 1945 1508 1509
43. K. Nicolaou, M. Zak, B.S. Safina, A.A. Estrada, S.H. Lee, and M. Nevalainen Total synthesis of thiostrepton. Assembly of key building blocks and completion of the synthesis J. Am. Chem. Soc. 127 2005 11176 11183
44. J.Y. Hwang, R.R. Attia, F. Zhu, L. Yang, A. Lemoff, C. Jeffries, M.C. Connelly, and R.K. Guy Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors J. Med. Chem. 55 2012 2301 2310
45. H.C. Kolb, M. Finn, and K.B. Sharpless Click chemistry: diverse chemical function from a few good reactions Angew. Chem. Int. Ed. 40 2001 2004 2021
46. A. Srivastava, J. Yano, Y. Hirozane, G. Kefala, F. Gruswitz, G. Snell, W. Lane, A. Ivetac, K. Aertgeerts, J. Nguyen, A. Jennings, and K. Okada High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 Nature 513 2014 124 127
47. D.J. St. Jean Jr., and C. Fotsch Mitigating heterocycle metabolism in drug discovery J. Med. Chem. 55 2012 6002 6020
48. M. Iwaoka, S. Takemoto, and S. Tomoda Statistical and theoretical investigations on the directionality of nonbonded S⋯O interactions. implications for molecular design and protein engineering J. Am. Chem. Soc. 124 2002 10613 10620
49. B.R. Beno, K.-S. Yeung, M.D. Bartberger, L.D. Pennington, and N.A. Meanwell A survey of the role of noncovalent sulfur interactions in drug design J. Med. Chem. 58 2015 4383 4438
50. D.K. Dalvie, A.S. Kalgutkar, S.C. Khojasteh-Bakht, R.S. Obach, and J.P. O'Donnell Biotransformation reactions of five-membered aromatic heterocyclic rings Chem. Res. Toxicol. 15 2002 269 299
51. A. Bondi van der Waals volumes and radii J. Phys. Chem. 68 1964 441 451
52. S. Sasaki, S. Kitamura, N. Negoro, M. Suzuki, Y. Tsujihata, N. Suzuki, T. Santou, N. Kanzaki, M. Harada, Y. Tanaka, M. Kobayashi, N. Tada, M. Funami, T. Tanaka, Y. Yamamoto, K. Fukatsu, T. Yasuma, and Y. Momose Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists J. Med. Chem. 54 2011 1365 1378
53. M.S. Winzell, and B. Ahrén The high-fat diet-fed mouse a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes Diabetes 53 2004 215 219
54. J.A. Koehler, L.L. Baggio, B.J. Lamont, S. Ali, and D.J. Drucker Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice Diabetes 58 2009 2148 2161